Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Flu has now reached California, officials at the California Department of Public Health (CDPH) confirmed on Tuesday. The mutated influenza strain, which is dubbed as the 'super flu' is now spreading in California.

The CDPH confirmed a second pediatric death related to flu since the season of this respiratory virus had started. The 'super flu' strain is the mutation of seasonal influenza A H3N2 virus, called the subclade K. While the cases are on the rise, with some record breaking ER visits and hospitalizations, the Centers for Disease Control and Prevention (CDC) noted that the season has not peaked yet, and that there might be more cases in the coming week.

What Are The Symptoms Of Super Flu?

Dr Monica Gandhi, who is an infectious disease expert at UC San Francisco told SFGATE that people infected with the mutated strain will likely get common flu symptoms, such as body aches, fever, cough and headache. "I think this particular strain makes people feel pretty horrible," Gandhi said, and further added, "And the reason that subclade K is important is it may not be covered by the current flu vaccine."

However, experts are still asking people to get vaccinated. In fact, the CDC has also noted that vaccination "has been shown to reduce the risk of flu and its potentially serious complications". However, only 130 million doses of vaccine have been distributed, which covers less than 40% of the US population. "The vaccine remains the most effective means to prevent disease. We still want to encourage people to get the vaccine," said Professor Antonia Ho, Professor and Honorary Consultant in Infectious Diseases at the University of Glasgow. Experts have stressed enough on the immunity that one can receive from the vaccine that that these flu jab remain the best defense against the flu, even though the current strain circulated may have drifted away from the strain included in this year's jab.

Data from the UK Health Security Agency (UKHSA) also show that vaccines is performing as expect, despite the emergence of subclade K.

K variant causes more intense flu symptoms, they include:

• Fever
• Chills
• Headache
• Fatigue
• Cough
• Sore throat
• Runny nose

This year's flu came after the flu vaccination was made, which means the current vaccination does not align with the mutation, however, experts have pointed out that it still continues to offer protection against the illness.

Update On Flu Activity

Flu activity in the state has shown a downtick from the season high at the end of the December. 15% of flu tests have come back positive by January 3, which is down from 17% rate seen during the week ending with December 27. However, the CDC noted that this downtick does not mean the end of flu season, it could rather mean that less cases were reported due to the holiday season. As the agency has warned more such cases to show up in the coming week.

In fact, hospitalization have been on the rise and hit a season high with 3.8 admissions per 100,000 in the state as of January 3.

Diabetes isn't just costing Indians their lifelong savings, it's also costing the country INT11.4 trillion.

According to a Nature Medicine study, India faces the second highest economic burden due to this chronic condition. Only the United States ranks higher, with costs touching INT 16.5 trillion, while China comes in third at INT 11 trillion.

While excluding informal care provided by family members, the global costs comes around INT 10 trillion which is about 0.2 per cent of the world’s annual gross domestic product (GDP).

However, if informal care is factored in, costs goes up to INT152 trillion or 1.7 per cent of the world’s yearly GDP, as per the study. (An international dollar, or INT$, is a statistical unit that has the same purchasing power as a US dollar).

The scientists estimated that the economic impact of diabetes was much more than Alzheimer’s disease or cancer in the top three countries.

The Diabetes Crisis In India

Diabetes is a chronic condition affecting several aspects of physical and mental health. It occurs when either the body can’t make enough insulin or can’t use it effectively, which impairs several functions.

Often referred to as the 'Diabetes capital of the world', over 100 million people across India suffer from the chronic condition while another 136 million are living with prediabetes.

According to Pharmeasy 2025 Diabetes Report, one in two people show high blood sugar levels when tested and over 90 percent of reports with high blood sugar also showed abnormality in one or the other parameters for liver, lipid, heart or thyroid issues.

Also known as a 'Silent Killer', diabetes can develop and progress quietly in the body, often without clear or early symptoms. Multiple studies show that over 50 percent of people with diabetes in India are undiagnosed or unaware of their condition.

When left undiagnosed and untreated, diabetes can cause severe complications across the body including heart disease, kidney damage or vision loss. These complications disproportionately affect vulnerable parts of the population, especially those in rural areas without access to proper testing and treatment.

Despite the growing economic burden, India faces systemic challenges in addressing diabetes, including inadequate healthcare infrastructure, low public awareness and fragmented policy responses.

What Did The Study Find?

They evaluated costs based on medical expenses, productivity losses and caregiving.

While the burden in the US is largely due to high treatment costs and loss of physical capital, the high costs are mainly driven by the sheer number of people affected in India and China, the researchers said.

Author Klaus Prettner, professor of macroeconomics and digitalization at the Vienna University of Economics and Business noted of the results: "Caregivers often drop out of the labor market, at least partially, which creates additional economic costs."

"This is a stark illustration of how medical treatment regimes for chronic diseases such as diabetes are accessible to high income countries only," co-author Michael Kuhn, acting economic frontiers research group leader at the International Institute for Applied Systems Analysis, added.

Based on the results, the scientists said promoting healthier lifestyle, regular physical activity and a balanced diet is the most effective way to prevent diabetes and reduce its economic impact in each country in the long run.

Colleen Hoover, the best-selling author of 'Regretting You' and 'Verity', has revealed that she has undergone treatment for cancer.

On January 12, Hoover announced via her Instagram Stories that she has one more day of radiation left at Texas Oncology.

"Second to last day of radiation," she captioned the post on her Instagram Stories. "I wish I could blame my hair and facial expressions on @Texas.Oncology, but they've been great. Hope you never need them, but highly recommend them."

In December 2025, the 46-year-old writer wrote on her Facebook page that she had been diagnosed with cancer and had undergone surgery. The film producer also noted that she would only need radiation, but not chemotherapy as a treatment plan.

Hoover said she had been in Canada filming Reminds of Him when she noticed she “had recurring health issues that I continued to put off until the movie was finished" and a check-up revealed that she had developed cancer.

What Kind Of Cancer Does She Have?

While she is yet to reveal which kind of cancer she is receiving treatment for, Hoover has confirmed it was not caused by family genes, HPV or excessive hormones.

In a Facebook post from January 9, she noted that the reason for her illness is 'more than likely' to be environmental/lifestyle, which can be credited to a lack of exercise, poor diet and stress.

"I’m happy and grateful to be alive but I hate vegetables. I hate when I have to get off the couch. I hate sweating. I hate when science is right. If you see me at the gym, don’t even tell me good job. If you see me at a restaurant eating grilled chicken and drinking water, I’m probably real mad about it," she wrote in a heartfelt moment.

Why Has Hoover Been Missing From Public Eye?

Hoover's health updates and cancer treatment come amid a series of cancelled public events. In October 2025, she announced she would not attend the premiere of Regretting You, her latest movie adaptation.

In a sentimental Instagram post, she told her fans: "I’m super bummed, but am having an unavoidable surgery and can’t travel for a while,” Hoover wrote in her Instagram post at the time. I’ll live vicariously through you guys. So sad to miss this movie release and premiere, but so grateful to all the actors and the team who put this together.”

Woman Down is Hoover’s next book release set for January 13. However, the author has had to tell fans that a book-signing tour has not been set up yet and she will not be meeting with the public for now.

“I wanted to make this post and be transparent about why that is. I’m not saying I won’t be up to doing at least one signing, but I just won’t know until I know," she said.

Meanwhile, throughout 2025, production on her hit novel, Verity, has begun in 2025, with Anne Hathaway and Josh Hartnett, being photographed during scenes last February. Additionally, her third movie adaptation, Reminders of Him, is also set to hit theaters on March 13, 2026.

It remains unknown if she will be attending the premiere for Reminders of Him.